ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

レボサルブタモール

(-)-Salbutamol

HCID 123600
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
34391-04-3
標準SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N
分子式
C13H21NO3
平均分子量
239.31 g/mol
単同位体質量
239.15214353

概要

(R)-salbutamol is an albuterol.

名称と識別子

優先名称
(-)-Salbutamol
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
現地名
レボサルブタモール
英語名
Levalbuterol
分子式
C13H21NO3
分子量
239.31

名称と別名

LevalbuterolLevosalbutamol(-)-Salbutamol34391-04-3(R)-salbutamol(-)-AlbuterolR-Salbutamol4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolEDN2NBH5SSASF-1096CHEBI:8746DTXSID80187964
名称をさらに表示
レバルブテロール(R)-1-[4-ヒドロキシ-3-(ヒドロキシメチル)フェニル]-2-(1,1-ジメチルエチルアミノ)エタノール2-(ヒドロキシメチル)-4-[(R)-1-ヒドロキシ-2-[(1,1-ジメチルエチル)アミノ]エチル]フェノール(αR)-α-[(tert-ブチルアミノ)メチル]-4-ヒドロキシ-1,3-ベンゼンジメタノール(R)-1-(4-ヒドロキシ-3-ヒドロキシメチルフェニル)-2-(1,1-ジメチルエチルアミノ)エタノール(R)-1-(4-ヒドロキシ-3-ヒドロキシメチルフェニル)-2-tert-ブチルアミノエタノール(R)-アルブテロール(R)-4-ヒドロキシ-3-ヒドロキシメチル-α-[(tert-ブチルアミノ)メチル]ベンジルアルコール(αR)-α-(tert-ブチルアミノメチル)-4-ヒドロキシ-3-(ヒドロキシメチル)ベンゼンメタノール(R)-サルブタモールレボサルブタモール(-)-サルブタモール(R)-4-ヒドロキシ-3-(ヒドロキシメチル)-α-[[(tert-ブチル)アミノ]メチル]ベンジルアルコール4-[(1R)-2-(tert-ブチルアミノ)-1-ヒドロキシエチル]-2-(ヒドロキシメチル)フェノールLEVALBUTEROL HCLSalbutamolr-albuterolLevalbutreol(L)-ALBUTEROLR-SALBUTAMOL HCLLEVOSALBUTEROLHCL
levosalbutamolum4-((1R)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenolAlbuterol (r)-Levalbuterol InhalationRefChem:56698Hydrochloride, LevalbuterolHydrochloride, LevosalbutamolDTXCID40110455

データベース識別子

CAS
34391-04-3
PubChem CID
123600
DTXSID
DTXSID80187964
ChEMBL
CHEMBL1002
ChEBI
CHEBI:8746
UNII
EDN2NBH5SS
EC Number
608-983-3
Nikkaji
J428.072E

物性

構造計算による物性

XLogP
0.3
極性表面積
72.7 Ų
水素結合供与体数
4
水素結合受容体数
4
回転可能結合数
5
重原子数
17
形式電荷
0
複雑度
227

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists
Collision Cross Section153.47 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

沸点
433.5 · 433.5±40.0 °C(Predicted)
比重(密度)
1.152 · 1.152±0.06 g/cm3(Predicted)
酸解離定数(Pka)
9.99 · 9.99±0.31(Predicted)
InChI
InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
InChIKey
NDAUXUAQIAJITI-PLAQIDKDNA-N
SMILES
C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|
CAS データベース
34391 · 34391-04-3(CAS DataBase Reference)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1 件

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

安全データ

hs_code
2922509090
risk_code
22
hazard_code
Xn
safety_code
36

化学と産業

薬理情報

Protein Bindingplasma protein binding is relatively low.
PharmacodynamicsIt acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
Mechanism of Action · 1 件

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Biological Half-Life3.3 - 4 hours
Metabolism/Metabolites · 2 件

Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6 件

EDN2NBH5SS

LEVALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.

LEVALBUTEROL

Absorption, Distribution and Excretion · 2 件

Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.

関連反応

3 件
反応記録を作成
HRID 1455720 の反応式
HRID 1455720生成物として
HRID 2375770 の反応式
HRID 2375770生成物として
HRID 2375771 の反応式
HRID 2375771生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

excreted into the urine.

用途と製造

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
応用分野 · 2 件

説明Levalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.

使用(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.

上流・下流製品情報

上流原料

5-アセチルサリチル酸メチルジメチル スルフィド ボラン水酸化パラジウム / 炭素tert-ブチルアミン臭化水素酸